The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
We used an atherogenic ApoE-deficient mouse (ApoE KO) model to determine whether treatment with recombinant (ApoM) would restore the impaired endothelium-dependent vasodilatation in these mice. Untreated ApoE KO mice, fed a high-cholesterol diet, were sacrificed at 25 (ApoE25, n = 5) or 30 weeks (ApoE30, n = 6). Treated mice received 20 (ApoM 20, n = 9) or 80 mg/kg/dose (ApoM 80, n = 10) of ApoM...
We previously demonstrated antiatherogenic effects of reconstituted high density lipoprotein (HDL) using the recombinant apolipoprotein (apo) A-I mutant, apoA-I Milano (ApoM), complexed with the phospholipid carrier DMPC. In this study, we examined whether ApoM has any effects on lysophosphatidylcholine (LPC)-induced impairment of endothelium-dependent vasodilatation...
Elevated plasma apolipoprotein (apo)-B level is a known risk for atherosclerotic CAD, however its relationship to arterial thrombosis is unknown. We prospectively assessed apo-B and platelet-dependent thrombosis (PDT) in 42 stable CAD patients on aspirin and lipid-lowering therapy, by exposing porcine aortic media to their flowing nonanticuagulated venous blood for 5 minutes at a shear rate of 800...